Pfizer Soars 19% To All-Time High After Parent Company’s Successful Vaccine Trials


Pfizer shares soared nearly 20 per cent to an all-time high on the BSE in early trading after its parent company, the US-based multinational pharma firm Pfizer said that its COVID-19 vaccine, developed in association with the German partner BioNTech SE, was more than 90 per cent effective against SARS-CoV-2, the novel coronavirus that causes Covid-19. Riding on the research developments, the shares of Pfizer opened at the day’s and all-time high of ₹ 5,875, up as much as 19.5 per cent, on the BSE. At 12:20 pm, the shares pared most of their gains and were trading at ₹ 5,100, up 3.7 per cent.

Pfizer and German partner BioNTech have been the first to release data showing that their vaccine worked in large, late-stage clinical trials and said they did not find any serious safety concerns as yet. They will be seeking US emergency use authorization this month.

READ  India is Repurposing Drugs to Maintain Supply Chain Across World: Expert Says